Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate
Abhisha Sawant Dessai1, Mayrel Palestino Dominguez1, Uan-I Chen2
1Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Abstract:
Metabolic dysregulation is a known hallmark of cancer progression, yet the oncogenic signals that promote metabolic adaptations to drive metastatic cancer remain unclear. Here, we show that transcriptional repression of mitochondrial deacetylase sirtuin 3 (SIRT3) by androgen receptor (AR) and its coregulator steroid receptor coactivator-2 (SRC-2) enhances mitochondrial aconitase (ACO2) activity to favor aggressive prostate cancer. ACO2 promoted mitochondrial citrate synthesis to facilitate de novo lipogenesis, and genetic ablation of ACO2 reduced total lipid content and severely repressed in vivo prostate cancer progression. A single acetylation mark lysine258 on ACO2 functioned as a regulatory motif, and the acetylation-deficient Lys258Arg mutant was enzymatically inactive and failed to rescue growth of ACO2-deficient cells. Acetylation of ACO2 was reversibly regulated by SIRT3, which was predominantly repressed in many tumors including prostate cancer. Mechanistically, SRC-2-bound AR formed a repressive complex by recruiting histone deacetylase 2 to the SIRT3 promoter, and depletion of SRC-2 enhanced SIRT3 expression and simultaneously reduced acetylated ACO2. In human prostate tumors, ACO2 activity was significantly elevated, and increased expression of SRC-2 with concomitant reduction of SIRT3 was found to be a genetic hallmark enriched in prostate cancer metastatic lesions. In a mouse model of spontaneous bone metastasis, suppression of SRC-2 reactivated SIRT3 expression and was sufficient to abolish prostate cancer colonization in the bone microenvironment, implying this nuclear-mitochondrial regulatory axis is a determining factor for metastatic competence. SIGNIFICANCE: This study highlights the importance of mitochondrial aconitase activity in the development of advanced metastatic prostate cancer and suggests that blocking SRC-2 to enhance SIRT3 expression may be therapeutically valuable. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/1/50/F1.large.jpg.
Insights
Androgen receptor (AR) and SRC-2 repress SIRT3, boosting ACO2 activity in aggressive prostate cancer. Blocking SRC-2 reactivates SIRT3, inhibiting metastasis and offering a potential therapy.
Area of Science:
- Molecular Oncology
- Cancer Metabolism
- Metastasis Research
Background:
- Metabolic dysregulation is a hallmark of cancer, but oncogenic signals driving metastatic adaptation are not fully understood.
- Sirtuin 3 (SIRT3), a mitochondrial deacetylase, plays a role in metabolic regulation, but its repression in cancer and impact on metastasis are unclear.
Purpose of the Study:
- To investigate the role of androgen receptor (AR), steroid receptor coactivator-2 (SRC-2), and mitochondrial aconitase (ACO2) in prostate cancer progression and metastasis.
- To elucidate the regulatory axis connecting nuclear signaling (AR/SRC-2) to mitochondrial metabolism (ACO2) and its impact on metastatic competence.
Main Methods:
- Investigated the transcriptional regulation of SIRT3 by AR and SRC-2.
- Assessed the enzymatic activity and regulatory acetylation of ACO2.
- Utilized genetic ablation of ACO2 and depletion of SRC-2 in prostate cancer models.
- Analyzed human prostate tumor samples for ACO2 activity, SRC-2, and SIRT3 expression.
Main Results:
- AR and SRC-2 repress SIRT3 expression, leading to increased ACO2 activity, which promotes lipogenesis and prostate cancer progression.
- Acetylation at Lys258 is crucial for ACO2 activity; SIRT3 deacetylates and regulates ACO2.
- SRC-2 depletion reactivates SIRT3, reduces acetylated ACO2, and abolishes bone metastasis in a mouse model.
Conclusions:
- The nuclear-mitochondrial regulatory axis involving AR, SRC-2, SIRT3, and ACO2 is critical for prostate cancer metastatic competence.
- Elevated ACO2 activity and specific expression patterns of SRC-2 and SIRT3 are hallmarks of metastatic prostate cancer.
- Therapeutic strategies targeting SRC-2 to enhance SIRT3 expression hold promise for treating metastatic prostate cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Co-activators and Co-repressors
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Epigenetic Regulation
X-chromosome...


